Sign In
Buy BMRN
$60.02
-0.560 (-0.92%)
At Close: Jul 31, 2026
BioMarin Files BLA for Gene Therapy to Treat Hemophilia A
09:30am, Tuesday, 24'th Dec 2019
BioMarin (BMRN) submits a BLA in the United States for its investigational gene therapy valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
BioMarin shares gain on positive dwarfism drug data
09:57am, Monday, 16'th Dec 2019
Shares of BioMarin Pharmaceutical Inc. BMRN, +2.17% are up 2.8% in morning trading on Monday following positive clinical findings from a Phase 3 trial for achondroplasia.
4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal
09:37am, Thursday, 05'th Dec 2019
Gene therapy continues to draw attention with the recent spate of deals and acquisitions. We list four stocks with promising candidates in their pipelines that make attractive acquisition targets.
Here's Why BioMarin Pharmaceutical Leapt 10.2% in November
01:21am, Wednesday, 04'th Dec 2019
The business reported a handful of positive developments.
REGN or BMRN: Which Is the Better Value Stock Right Now?
09:30am, Thursday, 28'th Nov 2019
REGN vs. BMRN: Which Stock Is the Better Value Option?
4 Big Drug Stocks Ripe for Takeover After NVS-MDCO Deal
06:07am, Tuesday, 26'th Nov 2019
Here are four stocks that boast promising prospects and are most likely to be takeout targets.
BioMarin Files MAA to EMA for Gene Therapy of Hemophilia A
10:29am, Friday, 22'nd Nov 2019
BioMarin (BMRN) submits an MAA in Europe for its investigational gene therapy valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
BioMarin (BMRN) Up 11% Since Last Earnings Report: Can It Continue?
09:31am, Friday, 22'nd Nov 2019
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?
BioMarin Pharmaceutical CEO: Substantial Profits Ahead
01:35pm, Friday, 15'th Nov 2019
BioMarin Pharmaceutical CEO Jean-Jacques Bienaimé chats with Jim Cramer about the impact of the recent FDA approval the company received for its hemophilia drug.
BioMarin CEO expects 'substantial' profitability after FDA approval of hemophilia drug
07:09pm, Thursday, 14'th Nov 2019
Jim Cramer chats with Jean-Jacques Bienaimé, chairman and CEO of BioMarin, which focuses on therapies to treat rare diseases.
2 Beaten-Down Biotech Stocks That Could Make You Rich
10:00am, Monday, 11'th Nov 2019
BioMarin and Sarepta Therapeutics should be top growth plays in the next decade.
Here's Why You Should Add BioMarin Pharmaceutical To Your Portfolio
09:03am, Monday, 04'th Nov 2019
Here's Why You Should Add BioMarin Pharmaceutical To Your Portfolio
